As biologics dominate biopharma pipelines, manufacturing hurdles trip up new launches: report

As biologics have come to supersede small molecules in the biopharma industry’s pipeline, the mounting complexity behind the manufacturing of those products is increasingly putting launches under p | As biologics have increasingly superseded small molecules in the biopharma industry’s pipeline, the mounting complexity behind the manufacturing of those products is putting production and launches under pressure.